Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02912845 · ClinicalTrials.gov registry record · Phase 3
Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to Rabies
A Phase 3 study of Rabies, sponsored by Kamada.
- Completed
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT02912845: Completed Phase 3 study of Rabies, sponsored by Kamada.
NCT02912845 is a Phase 3 study of Rabies that has completed, run by Kamada. The registered enrollment target is 30 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02912845, a Phase 3 study of Rabies, has completed, sponsored by Kamada.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary purpose of this study is to confirm the safety of KamRAB (Human Rabies Immunoglobulin) in children ages 0 months to \<17 years, when administered as part of post-Rabies Exposure Prophylaxis (PEP).
Conditions Studied
Interventions
- DRUG KamRAB - HRIG
Study Locations (1)
Arkansas
- ACH - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2016-08-01 |
| Est. Completion | 2019-11-13 |
| Phase | Phase 3 |
What the finished NCT02912845 record still lists
NCT02912845 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Rabies appearing as the primary indexed condition, and to 1 intervention - of which KamRAB - HRIG is the first listed.
NCT02912845 reports a single indexed study location in Arkansas.
Frequently Asked Questions
What is clinical trial NCT02912845 about?
NCT02912845 is a clinical study titled "Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to Rabies". The primary purpose of this study is to confirm the safety of KamRAB (Human Rabies Immunoglobulin) in children ages 0 months to \<17 years, when administered as part of post-Rabies Exposure Prophylaxis (PEP).
What is the current status of trial NCT02912845?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2016-08-01. Estimated completion is 2019-11-13.
What conditions does trial NCT02912845 study?
This clinical trial studies the following conditions: Rabies.
What interventions are being tested in trial NCT02912845?
The interventions under investigation include: KamRAB - HRIG (DRUG).
Who is sponsoring clinical trial NCT02912845?
This trial is sponsored by Kamada, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02912845 being conducted?
This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rabies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02912845's enrollment target sits among peer trials
30 1917th of 2000 higher than 68 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI